US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% SNDK $1,719.99 ▲+0.00% TSLA $370.59 ▲+0.00% SDEV $7.48 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.020 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
36 37 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are a hot topic on Tuesday morning as we start the day with a breakdown of all the latest stock market news! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
From Ocugen
Via GlobeNewswire
News headline image
Recap: Ocugen Q3 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Ocugen ↗
 
Via Benzinga
News headline image
Ocugen to Present at Pharma Market Research Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q3 2023 Earnings Call Transcript ↗
OCGN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Why Is Archer Aviation (ACHR) Stock Moving Today? ↗
Archer Aviation stock is on a wild ride Tuesday morning after a short report targeting one of its rivals sent ACHR shares down this morning. 
Via InvestorPlace
News headline image
Why Is Ocugen (OCGN) Stock Up 5% Today? ↗
Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine. 
Via InvestorPlace
News headline image
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
News headline image
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis 
From Ocugen
Via GlobeNewswire
News headline image
Ocugen (OCGN) Q2 2023 Earnings Call Transcript ↗
OCGN earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
36 37 Next >